Lower circulating SHBG levels have been correlated with markers of metabolic dysregulation, suggesting its possible utility as a biomarker for hyperinsulinaemia, insulin resistance and metabolic dysfunction-associated steatosis liver disease (MASLD). The gene discussed is SHBG; the disease is Insulin resistance.